1. Home
  2. SGMT vs EVC Comparison

SGMT vs EVC Comparison

Compare SGMT & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • EVC
  • Stock Information
  • Founded
  • SGMT 2006
  • EVC 1996
  • Country
  • SGMT United States
  • EVC United States
  • Employees
  • SGMT N/A
  • EVC N/A
  • Industry
  • SGMT
  • EVC Broadcasting
  • Sector
  • SGMT
  • EVC Industrials
  • Exchange
  • SGMT Nasdaq
  • EVC Nasdaq
  • Market Cap
  • SGMT 230.3M
  • EVC 188.3M
  • IPO Year
  • SGMT 2023
  • EVC 2000
  • Fundamental
  • Price
  • SGMT $7.11
  • EVC $2.48
  • Analyst Decision
  • SGMT Strong Buy
  • EVC
  • Analyst Count
  • SGMT 7
  • EVC 0
  • Target Price
  • SGMT $26.57
  • EVC N/A
  • AVG Volume (30 Days)
  • SGMT 601.4K
  • EVC 196.9K
  • Earning Date
  • SGMT 08-13-2025
  • EVC 11-05-2025
  • Dividend Yield
  • SGMT N/A
  • EVC 8.06%
  • EPS Growth
  • SGMT N/A
  • EVC N/A
  • EPS
  • SGMT N/A
  • EVC N/A
  • Revenue
  • SGMT N/A
  • EVC $396,704,000.00
  • Revenue This Year
  • SGMT N/A
  • EVC $64.06
  • Revenue Next Year
  • SGMT N/A
  • EVC N/A
  • P/E Ratio
  • SGMT N/A
  • EVC N/A
  • Revenue Growth
  • SGMT N/A
  • EVC 25.34
  • 52 Week Low
  • SGMT $1.73
  • EVC $1.58
  • 52 Week High
  • SGMT $11.41
  • EVC $2.73
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 39.46
  • EVC 51.66
  • Support Level
  • SGMT $7.01
  • EVC $2.44
  • Resistance Level
  • SGMT $7.68
  • EVC $2.50
  • Average True Range (ATR)
  • SGMT 0.51
  • EVC 0.08
  • MACD
  • SGMT -0.02
  • EVC -0.00
  • Stochastic Oscillator
  • SGMT 39.03
  • EVC 55.56

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: